After a while since our last update on these stocks, we wanted to provide an update to our readers on their recent developments and what to expect in the.
Animal health (AH) is gaining more and more attention from investors as new companies go public amidst the biotech IPO frenzy. In this report, we’ll focus on three new.
Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to.
Sunesis (SNSS) The company presented a poster of an MD Anderson-sponsored trial of its investigational drug voseroxin plus decitabine. There was intriguing data with regard to the response rates. 30.
Sunesis Pharmaceuticals (NASDAQ: SNSS) is expected to report top-line data from the Phase III VALOR study in the third or fourth quarter of this year. The VALOR study is.
Insmed (NASDAQ: INSM) is expected to report top-line data from a Phase II trial of Arikace in non-tuberculosis mycobacteria (NTM) infection tomorrow morning. This is a double-blind placebo-controlled study that.
As Cytokinetics confirmed in its Q4 2013 conference call, it will report top-line data from the BENEFIT-ALS study in the second quarter of this year, precisely, at the American.
On the verge of shutting down just a few months ago, Genvec (NASDAQ: GNVC) has recently had a comeback that might last for a few more years if its partnered.
(jointly with Jason Chew) KaloBios (NASDAQ: KBIO) completed its initial public offering this past January, securing $61.5 million in proceeds to fund operations and it recently raised $30M in a.
Today, Amgen (NASDAQ: AMGN) and Cytokinetics (NASDAQ: CYTK) reported data from the Phase IIb ATOMIC-AHF study of i.v. omecamtiv mecarbil (OM) in patients with acute heart failure. As we hypothesized.
Galapagos NV Galapagos (Brussels: GLPG; Pink Sheets: GLPYY.PK) is a Belgian biotech company whose lead product is JAK1 inhibitor GLPG0634 for rheumatoid arthritis (RA) and Crohn’s disease (CD). Jason covered.
(With Patrick Crutcher) Today Vical (NASDAQ: VICL) reported top-line data from a Phase III trial of Allovectin-7 (A7) in patients with advanced melanoma. As we predicted in this article, the.
We would like to take a closer look at the upcoming results of Merrimack Pharmaceuticals’ (MACK) lead drugs, MM-398 and MM-121. MM-398 MM-398 is a liposomal formulation of irinotecan intended.
with Patrick Crutcher and Jason Chew Abbvie (ABBV) presented data on its oncology candidates at ASCO meeting and updated investors at Jefferies Healthcare Conference last week. The stock, like other.
Results from ATOMIC-AHF, a Phase IIb clinical trial of omecamtiv mecarbil, are quickly approaching. Cytokinetics (NASDAQ: CYTK) and partner Amgen (NASDAQ: AMGN) expect to release top-line data around mid-year, probably.
with Patrick Crutcher Vical (NASDAQ: VICL) is approaching the release of top-line data from a Phase III clinical trial of Allovectin-7 (A7) in patients with metastatic melanoma. According to the.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) is slated to review Melblez (previously known as Chemosat) on May 2nd. An FDA decision is expected on June 15th. Melblez is a.
On April 17th, Theravance (NASDAQ: THRX) and partner GlaxoSmithKline (LSE: GSK; NYSE: GSK) will sit in front of the FDA’s Pulmonary-Allergy Drugs Advisory Committee that will decide on whether to.
The IPO window was almost closed in 2008 when the financial crisis hit the markets worldwide. Companies looking to raise funds from the capital markets had to think it twice.
Exact Sciences Exact Sciences (NASDAQ: EXAS) is expected to release full data from the DeeP-C study for Cologuard, its colon cancer screening test. The company anticipates filing a premarket approval.